Listen as Jim Del Rosso, DO, announces the launch of Bimzelx. Dr Del Rosso comments on the innovative mechanism of action, clinical trial results, warnings, and efficacy of this groundbreaking injectable biologic agent for moderate-to-severe plaque psoriasis. 

UCB has announced that the US Food and Drug Administration has approved Bimzelx (bimekizumab) for the treatment of moderate-to-severe plaque psoriasis in adults 18 years and older. 

Bimzelx is the first and only approved psoriasis treatment that selectively inhibits interleukin 17A and interleukin 17F, 2 key cytokines that drive the inflammatory process. 

Bimzelx was evaluated in multiple Phase 3 studies, versus placebo and ustekinumab, versus placebo, and versus adalimumab. Patients treated with bimekizumab achieved superior levels of skin clearance at week 16 compared to patients who received ustekinumab, placebo, and adalimumab, with patients consistently reaching PASI-75 and PASI-90. Bimekizumab was also evaluated in a head-to-head study with secukinumab, with bimekizumab demonstrating superiority for complete skin clearance as measured by PASI-100. 

The groundbreaking biologic marks an important step forward in the treatment landscape for adults living with moderate-to-severe plaque psoriasis.